Investigation of oral macrolide prescriptions in Japan using a retrospective claims database, 2013–2018
PLOS ONE · 22.06.2023 · 18 (6) · e0287297
DOI: 10.1371/journal.pone.0287297 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift PLOS ONE, online erschienen am 22.06.2023. Verfasst von Satoshi Ide und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emerging and Reemerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Sendai, Japan. Hauptthemen laut MEDLINE: Common Cold, Anti-Infective Agents, Hypersensitivity. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Macrolide usage in Japan exceeds that in Europe and the United States. Investigating the actual conditions in which macrolides are used is important for identifying further interventions for appropriate antimicrobial use; however, this situation has not been evaluated in Japan. Therefore, we aimed to clarify the number of macrolide prescriptions and their changes before and after implementation of the Antimicrobial Resistance (AMR) Action Plan. In addition, we also investigated the names of diseases for which macrolides have been prescribed and the number of days of prescription. A retrospective observational study was conducted using JMDC claims data from January 2013 to December 2018. The proportion of all oral antimicrobials and macrolides used during this period and the diseases for which macrolides were used in the 3 years before and after the AMR Action Plan were determined separately for acute (< 14 prescription days) and chronic (> 14 prescription days) diseases. The number of prescriptions for macrolides constituted approximately 30% of those for all oral antimicrobials; of these, clarithromycin accounted for approximately 60%. Most prescriptions for acute diseases were for common cold, whereas allergic and dermatological diseases were included among chronic diseases. The names of these illnesses did not change before and after the AMR Action Plan. Overall, these results indicate that appropriate macrolide use involves a review of their use for common cold along with appropriate evaluation of their long-term use for skin and allergic diseases. They also indicate the need for further fact-finding studies and ongoing AMR measures.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Emerging and Reemerging Infectious Diseases, Graduate School of Medicine, Tohoku University, Sendai, Japan.
- Division of Infection Control and Prevention, Tokyo Medical and Dental University Hospital, Bunkyo City, Japan.
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku City, Tokyo, Japan.
- AMR Clinical Reference Center, Disease Control and Prevention Center, National Center for Global Health and Medicine, Shinjuku City, Tokyo, Japan.
- Department of Pediatric General Medicine, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Hyogo, Japan.
- Department of Infectious Diseases, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Bunkyo City, Tokyo, Japan.
ORCID-Profile: Satoshi Ide, Yoshiki Kusama
Zitieren
APA
Ide, S., Ishikane, M., Aoyagi, K., Ono, A., Asai, Y., Tsuzuki, S., Kusama, Y., Gu, Y., Kodama, E., & Ohmagari, N. (2023). Investigation of oral macrolide prescriptions in Japan using a retrospective claims database, 2013–2018. PLOS ONE, 18(6), e0287297. https://doi.org/10.1371/journal.pone.0287297
Vancouver
Ide S, Ishikane M, Aoyagi K, Ono A, Asai Y, Tsuzuki S, et al. Investigation of oral macrolide prescriptions in Japan using a retrospective claims database, 2013–2018. PLOS ONE. 2023;18(6):e0287297. doi:10.1371/journal.pone.0287297
BibTeX
@article{Ide2023,
author = {Ide, Satoshi and Ishikane, Masahiro and Aoyagi, Kensuke and Ono, Akane and Asai, Yusuke and Tsuzuki, Shinya and Kusama, Yoshiki and Gu, Yoshiaki and Kodama, Eiichi and Ohmagari, Norio},
title = {Investigation of oral macrolide prescriptions in Japan using a retrospective claims database, 2013–2018},
journal = {PLOS ONE},
year = {2023},
volume = {18},
number = {6},
pages = {e0287297},
doi = {10.1371/journal.pone.0287297}
}
EUVIMED